414
Antisense Oligonucleotides as Potential Drugs
Applied Antisense Oligonucleotide Technology
,
Wiley-Liss, pp. 129–145.
DeRose, V.J.
(2002)
Two
decades
of
RNA
catalysis,
Chem. Biol.
9
, 961–969.
Eckstein, F. (2000) Phosphorothioate oligodeoxy-
nucleotides: What is their origin and what
is unique about them?
Antisense Nucleic Acid
Drug Dev.
10
, 117–121.
Lebedeva, I., Stein, C.A. (2001) Antisense oligo-
nucleotides: promise and reality,
Annu. Rev.
Pharmacol. Toxicol.
41
, 403–419.
McManus, M.T.,
Sharp, P.A.
(2002)
Gene
silencing in mammals by small interfering
RNAs,
Nat. Rev. Genet.
3
, 737–747.
Miller, P.S. (1991) Oligonucleoside methylphos-
phonates as antisense reagents,
BioTechnology
9
, 358–362.
Nielsen, P.E. (1999) Peptide nucleic acids as
therapeutic agents,
Curr. Opin. Struct. Biol.
9
, 353–357.
Opalinska, J.B., Gewirtz, A.M. (2002) Nucleic
acid therapeutics: basic principles and recent
applications,
Nat.
Rev.
Drug
Discovery
1
,
503–514.
Primary Literature
Braasch, D.A., Corey, D.R. (2001) Locked nucleic
acid (LNA): ±ne-tuning the recognition of DNA
and RNA,
Chem. Biol.
8
, 1–7.
Doudna, J.A., Cech, T.R. (2002) The chemical
repertoire of natural ribozymes,
Nature
418
,
222–228.
Engels, J., Jaeger, A. (1982) A new synthesis
of nucleoside methylphosphonates,
Angew.
Chem.
94
, 931.
Epple, C., Leumann, C. (1998) Bicyclo(3.2.1)-
DNA, a new DNA analog with a rigid backbone
and flexibly linked bases: pairing properties
with complementary DNA,
Chem.
Biol.
5
,
209–216.
Gryaznov, S.M. (1999) Oligonucleotide N3
0
-
P5
0
phosphoramidates
as
potential
therap-
eutic agents,
Biochim. Biophys. Acta
1489
,
131–140.
Grillone, L.R., Lanz, R. (2001) Fomivirsen,
Drugs
Today
37
, 245–255.
Heasman, J. (2002) Morpholino oligos: making
sense of antisense?
Dev. Biol.
243
, 209–214.
Jensen, B., Wacheck, V., Heere-Ress, E., Schlag-
bauer-Wadl, H., Hoeller, C., Lucas, T., Ho-
ermann, M., Hollenstein, U., Wolff, K., Pe-
hamberger, H. (2000) Chemosensitisation of
malignant melanoma by
BCL2
antisense ther-
apy,
The Lancet
356
, 1728–1733.
Luger, S.M., O’Brien, S.G.O., Ratajczak, J., Rata-
jczak, M.Z., Mick, R., Stadtmauer, E.A., Now-
ell, P.C., Goldman, J.M., Gewirtz, A.M. (2002)
Oligodeoxynucleotide-mediated inhibition of
c-
myb
gene
expression
in
autografted
bone
marrow:
a
pilot
study,
Blood
99
,
1150–1158.
Manoharan, M. (2002) Oligonucleotide conju-
gates s potential antisense drugs with im-
proved uptake, biodistribution, targeted de-
livery, and mechanism of action,
Antisense
Nucleic Acid Drug Dev.
12
, 103–128.
Scherr, M., Rossi, J.J. (1998) Rapid determi-
nation and quantitation of the accessibility
to native RNAs by antisense oligodeoxynu-
cleotides in murine cell extracts,
Nucleic Acids
Res.
26
, 5079–5085.
Yuen, A.,
Halsey, J.,
Fisher, G.,
Advani, R.,
Moore, M., Saleh, M., Ritch, P., Harker, G.,
Ahmed, F., Jone, C., Polikoff, P., Keiser, W.,
Kwoh, J.,
Holmlund, J.,
Dorr, A.,
Sikic, B.
(2001)
Phase
I/II
Trial
of
ISI 3521,
an
Antisense
Inhibitor
of
PKC-Alpha,
with
Carboplatin and Paclitaxel in Non-Small Cell
Lung Cancer (May 12, 2001),
American Society
of Clinical Oncology’s 37
th
Annual Meeting
,San
Francisco, CA.
previous page 414 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online next page 416 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online Home Toggle text on/off